PAP
TARS icon

Persistent Asset Partners’s Tarsus Pharmaceuticals TARS Stock Holding History

Persistent Asset Partners’s Portfolio TARS Stock Details TARS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-6,556
Closed -$460K – 903
2026
Q1 		$460K Buy
+6,556
New +$458K 0.17% 117
2025
Q1 		– Sell
-15,477
Closed -$832K – 210
2024
Q4 		$832K Buy
+15,477
New +$703K 0.69% 42

Other funds holding TARS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Persistent Asset Partners's TARS Position: Q2 2026 in Review

Persistent Asset Partners sold out of Tarsus Pharmaceuticals (TARS) in Q2 2026, closing a stake of 6,556 shares — an estimated $460K sold.

Persistent Asset Partners first reported a position in TARS in Q4 2024 and held it in 2 quarters. The position peaked at $832K in Q4 2024. 257 funds tracked by Wall St. Rank hold TARS as of Q2 2026.

  • Persistent Asset Partners reported no remaining Tarsus Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 6,556 Tarsus Pharmaceuticals shares in Q2 2026, an estimated $460K.
  • Persistent Asset Partners first reported a position in Tarsus Pharmaceuticals in Q4 2024 and held it in 2 quarters.
  • Persistent Asset Partners's Tarsus Pharmaceuticals position peaked at $832K in Q4 2024.
  • 257 funds tracked by Wall St. Rank held Tarsus Pharmaceuticals as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.